IMS Health Stock Price, News & Analysis (NYSE:IMS)

$31.34 0.99 (3.26 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$30.35
Today's Range$30.37 - $31.34
52-Week Range$22.36 - $31.59
Volume4.03 million shs
Average Volume1.27 million shs
Market Capitalization$10.33 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About IMS Health (NYSE:IMS)

IMS Health logoIMS Health Holdings, Inc. (IMS) is an information and technology services company that provides solutions to its clients in the healthcare industry. The Company has its presence in over 100 countries. The Company's data set contains over 10 petabytes of data and over 500 million patient records. It serves healthcare organizations and life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community. The Company's principal information offerings include national information offerings, sub-national information offerings and OneKey. Its technology services offerings include technology solutions, real-world evidence solutions, and workflow analytics and consulting services. It offers technology services that include data warehousing, information technology (IT) outsourcing, software applications and other services.

Receive IMS News and Ratings via Email

Sign-up to receive the latest news and ratings for IMS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry IT Services & Consulting
Sub-IndustryN/A
SectorTechnology
SymbolNYSE:IMS
CUSIPN/A
Phone+1-203-4484600

Debt

Debt-to-Equity Ratio2.53%
Current Ratio1.12%
Quick Ratio1.12%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$0.42
Net IncomeN/A
Net Margins2.99%
Return on Equity5.62%
Return on Assets1.22%

Miscellaneous

Employees15,000
Outstanding Shares329,220,000

IMS Health (NYSE:IMS) Frequently Asked Questions

What is IMS Health's stock symbol?

IMS Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMS."

How were IMS Health's earnings last quarter?

IMS Health Holdings Inc (NYSE:IMS) issued its quarterly earnings results on Wednesday, July, 27th. The information technology services provider reported $0.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.38 by $0.03. The information technology services provider had revenue of $802 million for the quarter, compared to analyst estimates of $796.93 million. IMS Health had a return on equity of 5.62% and a net margin of 2.99%. The company's revenue was up 112.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.37 earnings per share. View IMS Health's Earnings History.

Who are some of IMS Health's key competitors?

How do I buy IMS Health stock?

Shares of IMS Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IMS Health's stock price today?

One share of IMS Health stock can currently be purchased for approximately $31.34.

How big of a company is IMS Health?

IMS Health has a market capitalization of $10.33 billion. IMS Health employs 15,000 workers across the globe.

How can I contact IMS Health?

IMS Health's mailing address is 83 Wooster Heights Road, DANBURY, CT 06810, United States. The information technology services provider can be reached via phone at +1-203-4484600.


MarketBeat Community Rating for IMS Health (IMS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about IMS Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IMS Health (NYSE:IMS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ABuyBuy
Consensus Rating Score: N/AN/A2.672.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$31.00$30.17
Price Target Upside: N/AN/A23.16% upside19.85% upside

IMS Health (NYSE:IMS) Consensus Price Target History

Price Target History for IMS Health (NYSE:IMS)

IMS Health (NYSE:IMS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
5/4/2016Topeka Capital MarketsBoost Price TargetBuy$29.00 -> $30.00N/AView Rating Details
3/24/2016Piper Jaffray CompaniesReiterated RatingOverweight$28.00 -> $32.00N/AView Rating Details
2/23/2016Leerink SwannReiterated RatingOutperformN/AView Rating Details
2/4/2016J P Morgan Chase & CoLower Price Target$38.00 -> $32.00N/AView Rating Details
2/4/2016BarclaysLower Price TargetEqual Weight$28.00 -> $26.00N/AView Rating Details
2/2/2016Deutsche BankLower Price TargetBuy$30.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

IMS Health (NYSE:IMS) Earnings History and Estimates Chart

Earnings by Quarter for IMS Health (NYSE:IMS)

IMS Health (NYSE IMS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2016Q216$0.38$0.41$796.93 million$802.00 millionViewListenView Earnings Details
5/3/2016Q116$0.38$0.42$749.34 million$774.00 millionViewN/AView Earnings Details
2/3/2016Q415$0.32$0.37$788.75 million$812.00 millionViewN/AView Earnings Details
10/29/2015Q315$0.32$0.38$740.98 million$735.00 millionViewListenView Earnings Details
4/24/2015Q115$0.31$0.38$626.89 million$632.00 millionViewN/AView Earnings Details
2/3/2015Q414$0.32$0.34$679.82 million$678.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.33$0.37$668.30 million$656.00 millionViewListenView Earnings Details
7/24/2014Q1$0.37$0.39$654.92 million$662.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

IMS Health (NYSE:IMS) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for IMS Health (NYSE:IMS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

IMS Health (NYSE IMS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.50%
Institutional Ownership Percentage: 90.25%
Insider Trades by Quarter for IMS Health (NYSE:IMS)
Institutional Ownership by Quarter for IMS Health (NYSE:IMS)

IMS Health (NYSE IMS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/23/2015Kevin C. KnightlySVPSell19,231$28.50$548,083.50View SEC Filing  
11/19/2015Kevin C. KnightlySVPSell55,000$28.37$1,560,350.00View SEC Filing  
5/12/2015Cpp Investment Board Private HMajor ShareholderSell30,554,584$26.68$815,196,301.12View SEC Filing  
4/9/2014Cpp Investment Board Private HMajor ShareholderSell11,990,976$19.10$229,027,641.60View SEC Filing  
4/9/2014John G DanhaklDirectorSell2,463,899$20.00$49,277,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

IMS Health (NYSE IMS) News Headlines

Source:
DateHeadline
Analyzing Science Applications International (SAIC) and IMS Health (IMS)Analyzing Science Applications International (SAIC) and IMS Health (IMS)
www.americanbankingnews.com - December 13 at 9:18 PM
KeyBanc: Iqvia Holdings Valuation Might Be OverheatedKeyBanc: Iqvia Holdings' Valuation Might Be Overheated
finance.yahoo.com - November 13 at 7:55 PM
QuintilesIMS Reports Third-Quarter 2017 ResultsQuintilesIMS Reports Third-Quarter 2017 Results
www.thestreet.com - October 26 at 11:44 PM
Quintiles IMS Holdings’ (Q) Upgraded to BuyQuintiles IMS Holdings’ (Q) Upgraded to Buy
investorplace.com - October 20 at 5:13 AM
Quintiles IMS Holdings’ (Q) Shares Have Buy Rating Remain in PlaceQuintiles IMS Holdings’ (Q) Shares Have Buy Rating Remain in Place
investorplace.com - October 6 at 2:57 AM
QuintilesIMS to Host Financial Analyst and Investor Conference on November 8, 2017QuintilesIMS to Host Financial Analyst and Investor Conference on November 8, 2017
www.businesswire.com - October 4 at 5:23 PM
Why You Need To Look At This Factor Before Buying Quintiles IMS Holdings Inc (Q)Why You Need To Look At This Factor Before Buying Quintiles IMS Holdings Inc (Q)
finance.yahoo.com - October 2 at 11:12 PM
Head-To-Head Review: Total System Services (TSS) and IMS Health Holdings (IMS)Head-To-Head Review: Total System Services (TSS) and IMS Health Holdings (IMS)
www.americanbankingnews.com - September 23 at 6:30 AM
QuintilesIMS Announces Pricing on Offering of Senior NotesQuintilesIMS Announces Pricing on Offering of Senior Notes
www.nasdaq.com - September 11 at 8:28 PM
QUINTILES IMS HOLDINGS, INC.QUINTILES IMS HOLDINGS, INC.
www.streetinsider.com - September 11 at 8:28 PM
Quintiles IMS Incorporated -- Moodys rates Quintiles IMSs new Euro notes Ba3Quintiles IMS Incorporated -- Moody's rates Quintiles IMS's new Euro notes Ba3
finance.yahoo.com - September 11 at 8:28 PM
Quintiles Transnational Corp. -- Moodys assigns Ba1 rating to QuintilesIMS term loan B; Ba2 CFR affirmed; outlook revised to negativeQuintiles Transnational Corp. -- Moody's assigns Ba1 rating to QuintilesIMS' term loan B; Ba2 CFR affirmed; outlook revised to negative
finance.yahoo.com - September 6 at 7:47 PM
Oxford Immunotec Appoints Stefan Linn as Chief Operating OfficerOxford Immunotec Appoints Stefan Linn as Chief Operating Officer
www.nasdaq.com - August 31 at 6:09 AM
Oxford Immunotec (OXFD) Names Stefan Linn as New COOOxford Immunotec (OXFD) Names Stefan Linn as New COO
www.streetinsider.com - August 31 at 6:09 AM
Drug Giants Are Hunting for Patients in Indias Remote CornersDrug Giants Are Hunting for Patients in India's Remote Corners
www.bloomberg.com - August 2 at 11:24 PM
QuintilesIMS to Announce Second-Quarter 2017 Results on August 3, 2017QuintilesIMS to Announce Second-Quarter 2017 Results on August 3, 2017
www.businesswire.com - July 20 at 11:39 PM
Fortune 500 co. sells Houston health tech co. following revenue slideFortune 500 co. sells Houston health tech co. following revenue slide
www.bizjournals.com - July 19 at 3:26 AM
EQT to acquire pharmaceutical services firm CertaraEQT to acquire pharmaceutical services firm Certara
www.reuters.com - July 12 at 4:52 AM
EQT nears deal to acquire pharma services firm Certara: sourcesEQT nears deal to acquire pharma services firm Certara: sources
www.businessinsider.com - July 12 at 4:52 AM
PAVmed Inc. Closes $5 Million FinancingPAVmed Inc. Closes $5 Million Financing
www.businesswire.com - July 6 at 5:55 AM
Biopharma Outsourcing Is Going Through Deal Bonanza in U.S.Biopharma Outsourcing Is Going Through Deal Bonanza in U.S.
www.bloomberg.com - June 21 at 3:36 PM
Pamplona Capital to take Parexel private for $4.5 blnPamplona Capital to take Parexel private for $4.5 bln
www.nasdaq.com - June 20 at 6:47 PM
Pamplona Capital to take Parexel private for $4.5 billionPamplona Capital to take Parexel private for $4.5 billion
www.reuters.com - June 20 at 6:47 PM
QuintilesIMS (Q) Approves Additional $1B BuybackQuintilesIMS (Q) Approves Additional $1B Buyback
www.streetinsider.com - May 24 at 5:50 PM
QuintilesIMS to Announce First-Quarter 2017 Results on May 3, 2017QuintilesIMS to Announce First-Quarter 2017 Results on May 3, 2017
www.businesswire.com - April 19 at 5:46 PM
Cover Story: Inside one of Triangles hottest industries – CROsCover Story: Inside one of Triangle's hottest industries – CROs
www.bizjournals.com - March 10 at 7:06 PM
QuintilesIMS releases first earnings report as a combined companyQuintilesIMS releases first earnings report as a combined company
www.bizjournals.com - February 14 at 7:17 PM
Academics call time on $100,000 cancer drugsAcademics call time on $100,000 cancer drugs
uk.finance.yahoo.com - February 9 at 6:51 PM
Lonza agrees to buy Capsugel in $5.5 billion dealLonza agrees to buy Capsugel in $5.5 billion deal
www.marketwatch.com - December 15 at 4:40 AM
Lonza nearing $5 bln deal for KKRs CapsugelLonza nearing $5 bln deal for KKR's Capsugel
www.marketwatch.com - December 12 at 10:55 AM
Drug-Research Firm PPD Explores Sale - Wall Street JournalDrug-Research Firm PPD Explores Sale - Wall Street Journal
www.wsj.com - December 9 at 3:32 PM
Healthcare Tech Stocks With Upside Growth Potential - PR Newswire (press release)Healthcare Tech Stocks With Upside Growth Potential - PR Newswire (press release)
www.prnewswire.com - December 1 at 5:57 PM
Form 8-K Quintiles IMS Holdings, For: Nov 29 - StreetInsider.comForm 8-K Quintiles IMS Holdings, For: Nov 29 - StreetInsider.com
www.streetinsider.com - November 30 at 9:35 AM
The Big Q: Life after Quintiles-IMS mergerThe Big Q: Life after Quintiles-IMS merger
www.bizjournals.com - November 25 at 10:51 AM

SEC Filings

IMS Health (NYSE:IMS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

IMS Health (NYSE:IMS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

IMS Health (NYSE IMS) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.